PSMB8 and rheumatoid arthritis: However, most well-characterized proteasome inhibitors mediate the equivalent inhibition of both proteasome chymotrypsin-like activities (β5 and β5i = LMP7) [145,146] and have considerable toxicities that probably limit their clinical utility in chronic inflammatory diseases such as RA [147,148].